Epizyme, Inc. – Trademark Portfolio
Entity Type: 03
Epizyme, Inc. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include EPIZYME, TAZVERIK, and EPIZYMENOW. The owner is based in Cambridge, MA.
400 Technology Square
Cambridge, MA 02319
Showing of trademarks Trademarks
Trademark Classifications
Epizyme, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Insurance; financial affairs; monetary affairs; real estate affairs
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Epizyme, Inc. have?
Epizyme, Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 7 registered, 2 abandoned.
What trademark classes does Epizyme, Inc. file in?
Epizyme, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 36 (Insurance & Financial), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Epizyme, Inc.'s most well-known trademarks?
Epizyme, Inc.'s registered trademark portfolio includes well-known marks such as EPIZYME, TAZVERIK, and EPIZYMENOW. These are among 7 currently registered trademarks in the portfolio.
What is Epizyme, Inc.'s trademark registration success rate?
Epizyme, Inc. has a 78% trademark registration rate, with 7 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.